Semaglutide is a GLP-1 receptor agonist that helps support weight loss by acting like a natural hormone involved in blood sugar control and appetite regulation
As the third most common CV disease, VTE carries with it a substantial burden of deatharound 20%and short- and long-term complications related to both disease (e.g., recurrence, post-thrombotic syndrome) and treatment (i.e., major bleeding associated with anticoagulation treatment) [3, 4]
Cornell S
Sermorelin is a gentle GHRH analog with a short half-life, described as well suited to adults over 40 wanting steady, age-appropriate restoration
Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities
The medication's effect on appetite is secondary rather than primary, making it less potent for weight loss than medications designed specifically to target appetite centers in the brain